Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for COVID-19 Prophylaxis in Cancer Patients Receiving Radiotherapy
NCT04381988Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine with Placebo (2 arms). Primary endpoint: Cumulative Incidence of SARS-CoV-2 Infection at 9 weeks. Started May 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04381988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381988.